We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals
XFOR

49 hedge funds and large institutions have $98.4M invested in X4 Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

257% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 7

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

14% more funds holding

Funds holding: 43 → 49 (+6)

0.04% more ownership

Funds ownership: 2.04% → 2.08% (+0.04%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

14% less capital invested

Capital invested by funds: $114M → $98.4M (-$15.6M)

Holders
49
Holders Change
+6
Holders Change %
+13.95%
% of All Funds
1.07%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
9
Increased
25
Reduced
7
Closed
3
Calls
$636K
Puts
–
Net Calls
+$636K
Net Calls Change
-$114K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.3M
2
Northern Trust
Northern Trust
Illinois
+$1.16M
3
State Street
State Street
Massachusetts
+$806K
4
Millennium Management
Millennium Management
New York
+$488K
5
N
Nuveen
North Carolina
+$269K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$5.06M
2
First Eagle Investment Management
First Eagle Investment Management
New York
-$536K
3
Goldman Sachs
Goldman Sachs
New York
-$227K
4
CAM
Cormorant Asset Management
Massachusetts
-$115K
5
TRCT
Tower Research Capital (TRC)
New York
-$30K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
51
Tower Research Capital (TRC)
New York
– -$30K -66 Closed
MAM
52
Meeder Asset Management
Ohio
– -$3K -7 Closed
1 2
3

XFOR Hedge Fund Activity: Q3 2019 in Review

49 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q3 2019, worth a combined $98.4M — down 14% from $114M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new XFOR positions and 3 closed out — a net gain of 6 holders — while 25 added to existing stakes and 7 trimmed.

The largest buyer was BlackRock, adding an estimated $3.3M. The largest seller was RA Capital Management, cutting an estimated $5.06M.

  • 49 institutional investors held X4 Pharmaceuticals (XFOR) as of Q3 2019, up from 43 in Q2 2019.
  • Funds reported $98.4M of X4 Pharmaceuticals stock for Q3 2019, down 14% quarter-over-quarter.
  • 9 funds opened new X4 Pharmaceuticals positions in Q3 2019 and 3 closed out, a net change of +6 holders.
  • The largest X4 Pharmaceuticals buyer in Q3 2019 was BlackRock, an estimated $3.3M added.
  • The largest X4 Pharmaceuticals seller in Q3 2019 was RA Capital Management, an estimated $5.06M sold.

Based on aggregated 13F filings for Q3 2019.